title: Noninvasive prenatal testing for fetal aneuploidy: clinical assessment and a plea for restraint.
abstract: The recent introduction of clinical tests to detect fetal aneuploidy by analysis of cell-free DNA in maternal plasma represents a tremendous advance in prenatal diagnosis and the culmination of many years of effort by researchers in the field. The development of noninvasive prenatal testing for clinical application by commercial industry has allowed much faster introduction into clinical care, yet also presents some challenges regarding education of patients and health care providers struggling to keep up with developments in this rapidly evolving area. It is important that health care providers recognize that the test is not diagnostic; rather, it represents a highly sensitive and specific screening test that should be expected to result in some false-positive and false-negative diagnoses. Although currently being integrated in some settings as a primary screening test for women at high risk of fetal aneuploidy, from a population perspective, a better option for noninvasive prenatal testing may be as a second-tier test for those patients who screen positive by conventional aneuploidy screening. How noninvasive prenatal testing will ultimately fit with the current prenatal testing algorithms remains to be determined. True cost-utility analyses will be needed to determine the actual clinical efficacy of this approach in the general prenatal population.
authors: Department of Obstetrics and Gynecology, Stanford University School of Medicine/Lucile Packard Children's Hospital, Stanford, California; Intermountain Healthcare, University of Utah School of Medicine, Intermountain Medical Center, Maternal Fetal Medicine, Salt Lake City, Utah; and the Department of Genetics and Developmental Biology, University of Connecticut Health Center, Farmington, Connecticut.
authors: Mary E
authors: ME
authors: Norton
authors: Nancy C
authors: NC
authors: Rose
authors: Peter
authors: P
authors: Benn
mesh_terms: D000782:Aneuploidy; D004247:DNA / Q000097:blood; D005260:Female; D005315:Fetal Diseases / Q000175:diagnosis*; D005820:Genetic Testing; D006801:Humans; D011247:Pregnancy; D011296:Prenatal Diagnosis / Q000379:methods*; D011786:Quality Control
chemical_list: D004247:DNA
references: Ferreira-Gonzalez A, Teutsch S, Williams MS, Au SM, Fitzgerald KT, Miller PS, et al.. US system of oversight for genetic testing: a report from the Secretary's Advisory Committee on Genetics, Health and Society. Per Med 2008;5:521–8.
references: Screening for fetal chromosomal abnormalities. ACOG Practice Bulletin No. 77. American College of Obstetricians and Gynecologists. Obstet Gynecol 2007;109:217–27.
references: Invasive prenatal testing for aneuploidy. ACOG Practice Bulletin No. 88, December 2007. American College of Obstetricians and Gynecologists. Obstet Gynecol 2007;110:1459–67.
references: Syngelaki A, Chelemen T, Dagklis T, Allan L, Nicolaides KH. Challenges in the diagnosis of fetal non-chromosomal abnormalities at 11–13 weeks. Prenat Diagn 2011;31:90–102.
references: Nicolaides KH, Syngelaki A, Ashoor G, Birdir C, Touzet C. Noninvasive prenatal testing for fetal trisomies in a routinely screened first-trimester population. Am J Obstet Gynecol 2012;207:374.e1–6.
references: Benn PA, Chapman AR. Ethical challenges in providing noninvasive prenatal diagnosis. Curr Opin Obstet Gynecol 2010;22:128–34.
references: Malone FD, Canick JA, Ball RH, Nyberg DA, Comstock CH, Bukowski R, et al.. First-trimester or second-trimester screening, or both, for Down’s syndrome. N Engl J Med 2005;353:2001–11.
references: Noninvasive prenatal testing for fetal aneuploidy. Committee Opinion No. 545. American College of Obstetricians and Gynecologists. Obstet Gynecol 2012;120:1532–4.
references: Ashoor G, Poon L, Syngelaki A, Mosimann B, Nicolaides KH. Fetal fraction in maternal plasma cell-free DNA at 11–13 weeks' gestation: effect of maternal and fetal factors. Fetal Diagn Ther 2012;31:237–43.